Does Guardant Health (GH) Face Greater Patent Risk After The USPTO Ruling?

• Guardant Health (NasdaqGS:GH) faces heightened legal pressure after a USPTO decision on TwinStrand Biosciences' Duplex Sequencing patent.
• The USPTO issued a final, non appealable confirmation that all claims in TwinStrand's core Duplex Sequencing patent are patentable.
• This confirmation underpins TwinStrand's ongoing willful patent infringement lawsuit that targets Guardant Health's use of Duplex Sequencing technology.
• The USPTO's validation of TwinStrand's Duplex Sequencing patent only captures part of the legal picture facing Guardant Health today. Our analysis turns up 2 warning signs (1 major) for Guardant Health as well.

For a broader view of opportunities in similar businesses, explore peer stocks in related testing and healthcare AI fields through 34 healthcare AI stocks.

Guardant Health runs blood and tissue testing for cancer, so any legal challenge to core sequencing methods affects how its assays are developed and sold across the healthcare industry. The firm also provides related data sets, which ties its business closely to the underlying intellectual property around DNA sequencing accuracy.

Does the team leading Guardant Health have what it takes? See our full breakdown of the management team's track record and compensation.

How does this USPTO ruling change the legal risk for Guardant Health?

The USPTO has confirmed the patentability of all 23 claims in TwinStrand’s core Duplex Sequencing patent, on top of an earlier decision upholding claims in a related patent. That confirmation is not appealable and supports the existing US$245.2m willful infringement judgment and 6% royalty on key Guardant Health assays already referenced in the broader investment discussion.

Does this confirmation shift the Guardant Health Narrative investors have been using?

The Narrative already treats patent obligations and royalties as a central risk that can cap the benefit from Shield volumes, Guardant360 pricing, and MRD growth. This USPTO decision reinforces that risk side rather than the growth catalysts, because it strengthens the legal footing behind the damages award and ongoing royalty burden through March 2033.

See how these catalysts shape Guardant Health's path to a $202 fair value.

What should investors watch next following this TwinStrand patent outcome?

The most concrete marker from here is how royalty and legal costs flow through Guardant Health’s reported results, starting with the already released Q3 2026 numbers and into upcoming quarters for 2027 guidance. Tracking the annual free cash flow burn range against management’s US$195m to US$205m 2026 target will show how tightly these payments constrain the cash story.

Add Guardant Health to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com